Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC25A | P30304 | 1/20 | 0.33 |
| ▸ | CDC25B | P30305 | 1/20 | 0.33 |
| ▸ | CDC25C | P30307 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15041803 | 0.78 | PARP1 (0.35) | CDC25ACDC25BCDC25C | |
| SCHEMBL10346132 | 0.66 | DNMT3B (0.38) | — | |
| SCHEMBL15035233 | 0.63 | P2RX4 (0.36) | — | |
| SCHEMBL8190136 | 0.60 | PTGDR2 (0.36) | CDC25ACDC25BCDC25C | |
| SCHEMBL1107770 | 0.58 | POLB (0.43) | — | |
| SCHEMBL8525523 | 0.58 | POLB (0.43) | — | |
| SCHEMBL9878072 | 0.58 | HTR2A (0.33) | — | |
| SCHEMBL692925 | 0.58 | LTA4H (0.37) | — | |
| SCHEMBL18186976 | 0.56 | KEAP1 (0.50) | — | |
| SCHEMBL16831976 | 0.56 | KEAP1 (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | PAK5, PAK2, PAK6 | CDC25A 399/4885CDC25B 329/4885CDC25C 327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.